Improvement in treatment of hypothyroidism using slow-release Liothyronine

Phase 2

• Conditions: Hypothyroidism.; Hypothyroidism, unspecified; E03.9

• Registration Number: IRCT20100922004794N13
• Lead Sponsor: Dorsa Pharmaceutical Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Hypothyroid patients over 20 yrs. due to radioactive iodine intake for treating Graves’ Disease, who attained euthyroid status with LT4 monotherapy (TSH=0.5-5 mU/L is optimal).

Exclusion Criteria

Pregnancy, chronic kidney or liver disease, congestive heart failure, cancer, taking methimazole, PTU, Tamoxifen, estrogen, progesterone, and corticosteroids

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
T3/T4 ratio. Timepoint: 8 weeks after intervention. Method of measurement: Serum Total tri-iodothyronine(TT3), total thyroxine (TT4) will be determined on -20ºC stored serum samples by the electrochemiluminescence immunoassay (ECLIA) method, using Roche Diagnostics kits and Roche/Hitachi Cobas e-411 analyzer (GmbH, Mannheim, Germany).